Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
I've questioned the writer of the article, see what she says. Sometimes they just focus on clinical but TYK2 is now massive since BMS approval, all coming out of the woodwork. Look at DICE today trying to jump onboard with IL17 inhibition, but the devil is in the detail, dicing around with reporting on mild Vs moderate of BMS compound data. Also number of patients, high dosage.
60 working days then for CTA approval...
So this reporter clearly researched the market yet chose to omit the Sareum compound. If my understanding is correct they need the companies permission to write about it. Why wouldn't Tim want to be mentioned in this article. Question for our chairman I think.
He's actually talking about il-17 and alopecia and vitiligo.
"
11.30 Spearheading a Novel Drug Candidate in Chronic Inflammatory Skin and Joint Diseases • Outlining the emerging story of IL-17A and F in inflammatory diseases • How to Optimize targeting an important cytokine pathway - MOA and unique molecule characteristics of the novel IL-17 drug candidate sonelokimab • Showcasing disease control by sonelokimab from a phase 2b trial in psoriasis • Broadening the spectrum - Preparing for success in HS and PsA
"
Only thing I would pick up on is that the phase 1 doesn't have to include the funding requirements to completion. John confirmed this in an investor meet q and a, as I asked the question. We've been told we need more funds for the 1b anyway so that's means they would need to have this to hand now which they don't so no issue with raising funds during phase 1 trial to complete phase 1 trial with MHRA.
Raising funds is not an issue imo. Appetite is there, I think Tim is saying No to most things these days.
https://www.businesswire.com/news/home/20220928005018/en/Sudo-Biosciences-Raises-37M-Series-A-Financing-to-Advance-Precision-TYK2-Therapeutics
Discrete buying more common over the last few weeks.
Can't see why you would think trial start would be delayed to next year, we've had specialist consultants on this for a long time now. As John said on the last call, they are making sure all their internal procedures are correct.
You've gone quite pessimistic potnak I must say, at the most exciting time in Sareum history. At these prices in load up time, the indication was that 160k buy, upward trend since that.
Until we are told otherwise the board strategy is to license preclinical or early clinical. The focus is clearly on tyk2 compounds at the moment and we are now approaching the early clinical stages. For an indication which has shown no serious adverse events confidence in this passing the P1a should be overwhelming, together with the huge amounts of preclinical data we will have I'm sure they have built a strong case for an excellent deal. Our NEDs wouldn't continue to associate themselves with a dead duck, they'd move on to something which has value. They see the value, the HNWI's can see the value. Higher volume days on a 14/15 day cycle, 250k ish.
Nothing else in the pipeline for Sareum, will they continue or sell up.
Look at Ventyx bio and tell me we are not massively undervalued. Our CHK1 completed P2 trials, once GSK announce progress with that and TYK2 has initial safety data we should be valued more accurately.
https://ventyxbio.com/pipeline/
https://www.edisongroup.com/publication/sotyktu-approval-positive-read-across-for-sdc-1801/31326/
Some good analyst comments in here:
https://m.uk.investing.com/news/stock-market-news/ventyx-biosciences-shares-surge-key-overhang-removed-says-analyst-432SI-2748539
Also did you notice the investors in Nimbus, Bill Gates... If only Parker had his ear.
Even Ventyx shoots up.
https://seekingalpha.com/news/3882039-ventyx-stock-soars-as-analysts-see-sotyktu-approval-sans-warning-a-win-for-tyk2-class
Sareum managed a whole percentage! Peel Hunt asleep at the wheel on this one at the minute. Tim put the RNS out, UK market reaction nil.
Investor reaction quicker than expected...
https://www.fiercebiotech.com/biotech/investors-flood-nimbus-125m-tyk2-programs-phase-3-launch
Scrambling to take a position in Nimbus tyk2. Yes we're earlier in the development but the funding and interest is off the scales at the minute. This will translate into our SP rising and big volume days ahead.
Whatever "they" choose to do with this today just try and remember how far we have come here. The class now has an approved drug and this will give confidence to the pharma world, big pharma will now want a tyk2 as the income potential is huge to ignore. BMS is first but plenty room for more.
The difference is dosing patients and healthy volunteers. Healthy volunteers still 2022, patients 2023. No slippage here.
Strong language from Tim which is what we need now, they're good, we're better.
Place your bets.
Exactly what we needed, now that tyk2 will be in the media it's perfect timing for Sareum to release our clinical program news.
Now that there is no black box warning this becomes the benchmark for data.
A good week ahead, a better month.
You would expect that the consultants we've had on trial design know how to complete the paperwork correctly. I have no doubts about the approval.
I only fear the lack of market reaction, until the P1a results are disclosed, end of year hopefully.
GSK would be crazy not to try and get an agreement in place for the remaining 27.5% of SRA737, they will be looking at all the data, of which there is a lot and hopefully coming to the right conclusion. They don't need a partner eating into their profits on this, get rid of them now and reap the rewards.
Enjoy bank holiday everyone